Skip to contentB
Bioxytran, Inc
B
BIXTBioxytran, Inc Q3 2015 · 10-Q
Revenue$110.78K$110.78K+167.0% vs Q3 2014 Net Income$206.25K$206.25KN/M vs Q3 2014 EPS Diluted$0.00$0.00— vs Q3 2014 Gross Profit$42,988+498.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bioxytran, Inc · CIK 1445815 · Engraved from SEC EDGAR
Operating Cash Flowderived$21,546+231.2% Margins · derivedGross margin38.8%+21.5 pt vs Q3 2014
Operating margin187.9%+2873.2 pt vs Q3 2014
Net margin186.2%+2876.1 pt vs Q3 2014
ended Sep 30, 2015 · filed Nov 12, 2015 · 43 d after period end